Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-07-23
DOI
https://doi.org/10.3324/haematol.2026.301120
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial

Laura Barr, Manohursingh Runglall, Jad Othman, Hughes de Lavallade et al.
Haematologica
Acute Myeloid Leukemia Research
article

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial

Laura Barr, Manohursingh Runglall, Jad Othman, Hughes de Lavallade, Jelena Jovanovic, Phoebe Aucken, Nigel Russell, Nicola Potter, Richard Dillon, Patrick Harrington, Michael Lim, Carlos Jiménez-Vicente, Jennifer O’Sullivan
article en

Abstract

No abstract available for this paper.
Haematologica
Guy's Hospital (GB), King's College - North Carolina (US), King's College London (GB), King's College Hospital (GB)
Amgen, Pfizer, Royal College of Pathologists of Australasia, Syndax Pharmaceuticals, Astellas Pharma, RCPA Foundation
Zero hunger
Openalex Percentile: Top 9%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.